Rituximab for Ocular Inflammatory Disease

Emmett T Cunningham Jr^{1

2

3}, Caleb Ng⁴, Eric B Suhler⁵, Derrick P Smit⁶

Affiliations

¹ The Department of Ophthalmology, California Pacific Medical Center, San Francisco, CA, USA.
² The Department of Ophthalmology, Stanford University School of Medicine, Stanford, CA, USA.
³ The Francis I. Proctor Foundation, UCSF School of Medicine, San Francisco, CA, USA emmett_cunningham@yahoo.com.
⁴ Retina Consultants of Orange County, Fullerton, CA, USA.
⁵ OHSU-PSU School of Public Health, and VA Portland Health Care System, Casey Eye Institute, Oregon Health & Science University, Portland, Oregon, USA.
⁶ Division of Ophthalmology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.

Editorial

Emmett T Cunningham Jr et al. Ocul Immunol Inflamm. 2022 Aug.

. 2022 Aug;30(6):1300-1302.

doi: 10.1080/09273948.2022.2141034.

Emmett T Cunningham Jr^{1

2

3}, Caleb Ng⁴, Eric B Suhler⁵, Derrick P Smit⁶

¹ The Department of Ophthalmology, California Pacific Medical Center, San Francisco, CA, USA.
² The Department of Ophthalmology, Stanford University School of Medicine, Stanford, CA, USA.
³ The Francis I. Proctor Foundation, UCSF School of Medicine, San Francisco, CA, USA emmett_cunningham@yahoo.com.
⁴ Retina Consultants of Orange County, Fullerton, CA, USA.
⁵ OHSU-PSU School of Public Health, and VA Portland Health Care System, Casey Eye Institute, Oregon Health & Science University, Portland, Oregon, USA.
⁶ Division of Ophthalmology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.

No abstract available

Comment on

Efficacy of Rituximab Treatment in Vogt-Koyanagi-Harada Disease Poorly Controlled by Traditional Immunosuppressive Treatment.
Bolletta E, Gozzi F, Mastrofilippo V, Pipitone N, De Simone L, Croci S, Invernizzi A, Adani C, Iannetta D, Coassin M, Fontana L, Salvarani C, Cimino L. Bolletta E, et al. Ocul Immunol Inflamm. 2022 Aug;30(6):1303-1308. doi: 10.1080/09273948.2021.1880604. Epub 2021 Apr 1. Ocul Immunol Inflamm. 2022. PMID: 33793383
Rituximab Attenuated Lipopolysaccharide-Induced Oxidative Cytotoxicity, Apoptosis, and Inflammation in the Human Retina Cells via Modulating the TRPM2 Signaling Pathways.
Daldal H, Nazıroğlu M. Daldal H, et al. Ocul Immunol Inflamm. 2022 Aug;30(6):1315-1328. doi: 10.1080/09273948.2022.2075400. Epub 2022 May 19. Ocul Immunol Inflamm. 2022. PMID: 35587813